PAP
PTHS

Persistent Asset Partners’s Pelthos Therapeutics PTHS Stock Holding History

Persistent Asset Partners’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126K Hold
6,007
– – 0.05% 229
2025
Q4 		$186K Buy
6,007
+3,604
+150% +$104K 0.08% 219
2025
Q3 		$67.3K Buy
+2,403
New +$58.3K 0.05% 170

Other funds holding PTHS

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Persistent Asset Partners's PTHS Position: Q1 2026 in Review

Persistent Asset Partners held its Pelthos Therapeutics (PTHS) position steady in Q1 2026 at 6,007 shares worth $126K. The position accounts for 0.05% of the portfolio, ranked #229.

Persistent Asset Partners first reported a position in PTHS in Q3 2025 and has held it in 3 quarters since. The position peaked at $186K in Q4 2025. 17 funds tracked by Wall St. Rank hold PTHS as of Q1 2026.

  • Persistent Asset Partners held 6,007 shares of Pelthos Therapeutics worth $126K as of Q1 2026.
  • Persistent Asset Partners left its Pelthos Therapeutics share count unchanged in Q1 2026.
  • Pelthos Therapeutics made up 0.05% of Persistent Asset Partners's portfolio in Q1 2026, its #229 holding.
  • Persistent Asset Partners first reported a position in Pelthos Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Persistent Asset Partners's Pelthos Therapeutics position peaked at $186K in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.